Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-05-02 | The following table shows the compensation paid in fiscal 2010 to the Companys non-employee directors. Joseph S. Zakrzewski Amounts for Mr. Zakrzewski represent fees paid to him as a non-employee director and do not include any amounts paid to Mr. Zakrzewski in his capacity as Chief Executive Officer. |
| 2012-04-27 | Joseph S. Zakrzewski was appointed as Executive Chairman of our Board of Directors effective January 2010, was appointed as our Chief Executive Officer effective November 10, 2010, and became Chairman of our Board of Directors effective October 20, 2011 in connection with his joining Amarin on a full-time basis. ... Amounts paid to Mr. Zakrzewski in his capacity as Chief Executive Officer and Director are set forth in the Summary Compensation Table above. ... Total compensation for 2011 was $5,196,945. |
| 2013-04-23 | Joseph S. Zakrzewski was appointed as Executive Chairman of our Board of Directors effective January 2010, was appointed as our Chief Executive Officer effective November 10, 2010, and became Chairman of our Board of Directors effective October 20, 2011 in connection with his joining Amarin on a full-time basis. The Board has concluded that Mr. Zakrzewski should serve on our Board based on his knowledge of our Company gained from his position as Chief Executive Officer and his substantial experience serving as an executive officer of other pharmaceutical companies. Amounts paid to Mr. Zakrzewski in his capacity as Chief Executive Officer and Director are set forth in the Summary Compensation Table above. The following table shows the compensation paid in fiscal 2012 to the Company’s non-employee directors. Joseph S. Zakrzewski: $3,679,380 in 2012. |
| 2014-04-30 | Joseph S. Zakrzewski (2010) 51 Director; No director compensation listed for 2013 as he was CEO until Dec 31, 2013 |
| 2015-04-24 | The following table shows the compensation paid in fiscal 2014 to the Company’s non-employee directors. Joseph S. Zakrzewski: $128,433. |
| 2016-04-29 | Joseph S. Zakrzewski joined Amarin as a non-executive director in January 2010... The Board has determined that Mr. Zakrzewski lacks independence because of his prior status as the Company’s Chief Executive Officer through December 31, 2013... The following table shows the compensation paid in fiscal 2015 to the Company’s non-employee directors... Joseph S. Zakrzewski 55,000 146,250 77,486 278,736 |
| 2017-04-21 | Joseph S. Zakrzewski (2010) 54 Director; The Nominating and Corporate Governance Committee is currently comprised of Mr. O'Sullivan (Chairman), Dr. Ekman and Mr. Zakrzewski; Director Compensation Table shows Joseph S. Zakrzewski compensation as $145,008. |
| 2018-04-20 | Joseph S. Zakrzewski (2010) 55 Director Nominating and Corporate Governance Committee is currently comprised of Mr. O'Sullivan (Chairman), Mr. Zakrzewski and Dr. Ekman. Director Compensation Table shows Joseph S. Zakrzewski fees earned or paid in cash $60,000, stock awards $45,000, option awards $45,005, total $150,005. |
| 2019-04-25 | Joseph S. Zakrzewski (2010) 56 Director; Nominating and Corporate Governance Committee is currently comprised of Mr. O'Sullivan (Chairman), Mr. Zakrzewski and Dr. Ekman; Director Compensation Table shows Joseph S. Zakrzewski total compensation $260,002. |
| 2020-06-01 | The Nominating and Corporate Governance Committee is currently comprised of Mr. O'Sullivan (Chairman), Mr. Zakrzewski and Dr. Ekman. On May 20, 2019, the Company awarded options representing the right to purchase 9,658 ordinary shares and 7,428 restricted stock units to Mr. Zakrzewski in connection with their service on the Board. The total grant-date fair value of each of these awards is $125,034 and $125,013, respectively. The following table shows the compensation paid in fiscal year 2019 to the Company’s non-employee directors: Joseph S. Zakrzewski Fees Earned or Paid in Cash: $60,000, Stock Awards: $125,013, Option Awards: $125,034, Total: $310,047. |
| 2021-04-29 | Joseph S. Zakrzewski joined Amarin as a non-executive director in January 2010. He serves on the Nominating and Corporate Governance Committee. Director compensation table shows total compensation of $427,506 in 2020. |
| 2022-05-24 | The Nominating and Corporate Governance Committee is currently comprised of Mr. O’Sullivan (Chairman), Mr. Zakrzewski and Dr. Ekman. The Remuneration Committee is currently comprised of Mr. Wold-Olsen (Chairman, effective as of May 2022), Mr. Stack (Chairman until the appointment of Mr. Wold-Olsen in May 2022), Ms. Peterson and Mr. van Heek. The total grant-date fair value of each of these awards is approximately $180,000, based on a closing price of $5.00 on Nasdaq of the ADSs representing the Company’s ordinary shares on the date of grant. Director Compensation Table: Lars G. Ekman, M.D., Ph.D. $100,000 fees earned in cash, $190,000 stock awards, $190,004 option awards, total $480,004; Jan van Heek $97,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $457,503; Patrick J. O’Sullivan $85,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $445,503; Kristine Peterson $84,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $444,503; David Stack $82,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $442,503; Joseph S. Zakrzewski $67,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $427,503. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-24 | Joseph S. Zakrzewski, age 55, has served as a member of our Board of Directors since June 2017. The Audit Committee consists of three directors: Mr. Carey, Ms. Ramasastry, and Mr. Zakrzewski. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2017. Joseph S. Zakrzewski: Total $188,229. |
| 2019-04-25 | Joseph S. Zakrzewski, age 56, has served as a member of our Board of Directors since June 2017. The Audit Committee consists of three directors: Mr. Carey, Ms. Ramasastry, and Mr. Zakrzewski. Director compensation table shows total compensation of $240,270. |
| 2020-04-02 | Joseph S. Zakrzewski, age 57, has served as a member of our Board of Directors since June 2017. The Compensation Committee consists of three directors: Ms. Parker, Dr. Smith and Mr. Zakrzewski. The Audit Committee consists of three directors: Mr. Carey, Dr. Dilly and Ms. Ramasastry. Mr. Zakrzewski received total compensation of $177,562. |
| 2021-04-02 | Joseph S. Zakrzewski, age 58, has served as a member of our Board of Directors since June 2017. Mr. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization. Prior to focusing on serving on boards and investments, from 2010 through 2013, he was Chairman and Chief Executive Officer of Amarin Corporation plc (formerly Amarin Pharmaceuticals, Inc.), where he led the development and commercialization of the company’s first product, Vascepa. Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors LLC, a venture capital firm, and as Chairman, President and Chief Executive Officer of Xcellerex, Inc., a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines. Earlier, he served as Chief Operating Officer of Reliant Pharmaceuticals, Inc. before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development. Mr. Zakrzewski currently serves on the board of directors of Acceleron Pharma, Inc., a public biopharmaceutical company, and Amarin Corporation plc, a public biopharmaceutical company. Mr. Zakrzewski previously served on the board of directors of Insulet Corporation, a public medical device company, from 2008 to August 2017. Mr. Zakrzewski received his B.S. in Chemical Engineering and M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University. The Nominating and Corporate Governance Committee and the Board believe that Mr. Zakrzewski’s significant experience as a Chief Executive Officer and leading a variety of functional areas including supply and manufacturing operations provides the Board with an important set of skills to assist in the oversight of the development of our novel genomic and cell therapy assets. The Compensation Committee consists of three directors: Mr. Meyers, Dr. Smith and Mr. Zakrzewski. Mr. Zakrzewski serves as Chair of this committee. Mr. Zakrzewski received total compensation of $295,172 in 2020. |
Data sourced from SEC filings. Last updated: 2026-02-03